Cost-Benefit Analysis

Antibioticoterapia parenterale a domicilio: un’opportunità mancata?

G. Vieni, F. Marchetti

2016/9 — pag. 602-604

La faringotonsillite in età pediatrica Aggiornamento delle linee guida della Regione Emilia-Romagna

S. Di Mario, C. Gagliotti, M.L. Moro, a nome del Gruppo "ProBA"

2015/7 — pag. 442-447

This guideline on acute pharyngitis in childhood updates the guideline published by the Emilia-Romagna Region in 2007. Acute pharyngitis is a frequent condition in childhood, causing repeated clinical visits, emergency department visits, and inappr...

Controproduttività

G. Tamburlini

2013/5 — pag. 279

Il pediatra e i disturbi gastrointestinali funzionali

G. Primavera, G. Magazzù

2011/5 — pag. 289-295

Even though functional gastrointestinal disorders (FGID) are often considered an example of disease mongering, their reported prevalence and costs prompt to take into consideration the most cost-effective approach that can be applied to primary car...

Vaccinazione anti-rotavirus:intervento lodevole ma… fa risparmiare il sistema sanitario nazionale?L’esperienza del Brasile

C. Centenari, G. Maggiore, R.Q. Gurgel, L.E. Cuevas

2011/3 — pag. 191-192

The present “budget impact” study assessed the family and health system costs due to diarrhoea in children < 2 years old, before/after the introduction of a rotavirus vaccine in Brazil in 2006. This kind of evaluations plays a crucial role in the ...

Vaccinazione anti-rotavirus: intervento lodevole ma… fa risparmiare il Sistema Sanitario Nazionale? L’esperienza del Brasile

C. Centenari, G. Maggiore, R.Q. Gurgel, L.E. Cuevas

2011/3

The present “budget impact” study assessed the family and health system costs due to diarrhoea in children < 2 years old, before/after the introduction of a rotavirus vaccine in Brazil in 2006. This kind of evaluations plays a crucial role in the ass...

Etica vaccinale differenziata e differita

2007/7 — pag. 453-454

Vaccini anti-rotavirus. quale? quando? perché? per chi?

M. Fontana

2007/3 — pag. 173-175

Two new Rotavirus vaccines are being dispensed soon in Italy. They differ strongly in composition and suggested schedule. Available studies do not allow direct comparisons (severity scales for gastroenteritis are different, as are the cut-off point...

Vaccinazione anti-varicellaAsma, steroidi inalatori e guaribilitàEmergency

2006/4 — pag. 217-221

Figli di un dio minore

R. Cavallo

2005/1 — pag. 31-35

The Puglia Region has recently established the free provision of pertussis, measles-mumps-rubella, Haemophilus, pneumococcal and meningococcal vaccines. The decision does not make any difference between vaccines which respond to well established pu...

Interventi preventivi tra equità, efficacia e ragione

F. Marchetti

2005/1 — pag. 7-11

Una nuova analisi costo-efficacia del vaccino coniugato contro lo pneumococco in Inghilterra e nel Galles

G. Bartolozzi

2004/11

Lo screening uditivo neonatale: una esperienza a misura di Nido

2002/5 — pag. 325-326

Report of an otoacoustic emissions screening carried out at a nursery. The cost calculated for each case of deep hearing loss identified at birth ranges from 1200 to 2400 Italian euro....

L’immunoterapia specifica orale: sì o no?

G. Longo

2001/9 — pag. 617-620

Desensitization through the sublingual route is very popular and covers about 50% of the market. There is general consensus on its biological efficacy but at a more careful scrutiny its widespread use does not appear totally justified. If costs, li...

Pielonefrite e reflusso vescico-ureterale

L. Peratoner, G. Manzoni

1999/9 — pag. 550-554

There is no consensus on the most cost-effective approach to the diagnosis of acute pyelonephritis (APN) and on the best therapeutic approach to vesicoureteral reflux (VUR). Not enough attention is payed to the diagnosis of urinary tract infection,...

Palivizumab: un anticorpo monoclonale umanizzato contro il virus respiratorio sinciziale

L. De Seta, G. Orso

1999/8 — pag. 491-494

Respiratory Syncytial Virus (RSV) is the main cause of respiratory infections in the first years of life. Preterm infants and those affected by broncopulmonary dysplasia (BPD) represent the categories at highest risk of severe RSV infections. Paliv...

La malattia del mercato

A. Donzelli

1997/9 — pag. 568-572

Vaccino tetravalente contro il Rotavirus: sì, forse sì, forse noRotavirus in NicaraguaPensieri sul diabete instabile dell’adolescente, ovvero navigazione tra teoria e praticaDisodiocromoglicato e asma del bambino: condanna in appelloTrattamento semplificato per Tinea cruris e Tinea corporisLa tossicità del paracetamoloPerché (qualche volta) la dermatite atopica guarisce dopo la varicella?Gli eosinofili “lavorano” anche se l’allergia non è IgE mediataEosinofili e olfattoMeningite batterica negli Stati Uniti: l’effetto del vaccino contro l’HibCambiamenti nell’epidemiologia dell’erpes simplex tipo 2

1997/9 — pag. 553-554

Vaccinazione anti-varicella: solo delirio vaccinale?

G. Palla, A. Villirillo, A. Ventura

1997/6 — pag. 381-385

Chickenpox is a self-limited disease in the large majority of cases. However, severe complications may occasionally occur both in immunocompetent (infections due to invasive beta-hemolytic group A streptococcus) and in immunocompromised children...

Costi-benefici dei vaccini antipertosse acellulari e anti-Hib

G. Bartolozzi

1997/1 — pag. 35-40

The Author proposes a cost/benefit analysis for pertussis and haemophilus type b vaccines. Cost/benefit of the new acellular pertussis vaccines is higher than for the wholecell vaccines due to the higher cost of the former, but better acceptance...

La vaccinazione contro il Rotavirus

G. Palla, A. Ventura

1997/1 — pag. 29-33

Rotavirus is the leading cause of severe diarrhoea in infants and causes an estimated 900.000 deaths annually in developing countries. In developed cauntries the rate of hospital admission for Rotavirus gastroenteritis is 3-10/1000 childrens age...